Prognostic Value of Biomarkers in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy
Main finding · Composite of acute cardiovascular hospitalization heart failure or deathResult — go to the resultAdjusted hazard ratio 1.29 95% CI 1.06–1.33Authors' conclusion
These data highlight NT-proBNP levels as a valuable marker for identifying cancer patients at increased risk for cardiovascular events during ICI therapy.
Study context
- Population
- Cancer patients treated with ICI who had available baseline NT-proBNP levels35% female, age 65 years
- Participants
- 550 patients
- Comparison
- Association of baseline NT-proBNP (per 1-SD increase in log-transformed biomarker) with cardiovascular hospitalization and death
- Outcome
- Composite of:
- Acute cardiovascular hospitalization heart failure
- Death
- Follow-up
- Median 67 weeks
Methodological detailssingle-centre (Vienna General Hospital), January 2017 to July 2022, multivariable Cox regression
- Single-centre (Vienna General Hospital)
- January 2017 to July 2022
- Multivariable Cox regression
Main finding
As reported in the abstract
Adjusted hazard ratio
1.29
95% CI 1.06–1.33
1-SD increase in log-transformed NT-proBNP
adjusted HR 1.29 (95% CI 1.06–1.33)
- Primary composite endpoint rate
- 46.7 events per 100 patient-years
Further findings
Baseline NT-proBNP levels
- Median NT-proBNP
- 272 pg/mL (Q1-Q3: 102-742)
- Patients with levels ≥125 pg/mL
- 388 patients (71%)
Death · median follow-up of 67 weeks
- Patients who died
- 190 patients (35%)
Cardiovascular hospitalizations (most commonly due to stroke, coronary artery disease, and heart failure) · median follow-up of 67 weeks
- Cardiovascular hospitalizations
- 103
- Patients with a cardiovascular hospitalization
- 76 patients (14%)
Original publication
Prognostic Value of Biomarkers in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy. JACC Adv. Published 31 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →